Minnesota Oncology/Hematology Associates of Central Illinois — Minneapolis, Minnesota

Minnesota Oncology/Hematology Associates of Central Illinois is a clinical research site located in Minneapolis, Minnesota, United States 55404.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Minnesota Oncology/Hematology Associates of Central Illinois has participated in 1 clinical trials.

Therapeutic areas: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.

Sponsors: Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Minneapolis

Browse all research sites in Minnesota · View every site in Minneapolis

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Minnesota Oncology/Hematology Associates of Central Illinois?

Minnesota Oncology/Hematology Associates of Central Illinois has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Minnesota Oncology/Hematology Associates of Central Illinois conducted?

Minnesota Oncology/Hematology Associates of Central Illinois has 1 clinical trials on record. Their work covers Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.

Is Minnesota Oncology/Hematology Associates of Central Illinois accredited by Crixeo Clinical Trials?

Minnesota Oncology/Hematology Associates of Central Illinois has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Minnesota Oncology/Hematology Associates of Central Illinois?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.